Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Quest and BC Cancer Agency team on lung cancer therapy
February 2008
SHARING OPTIONS:

EDMONTON, Alberta—In late January, Quest PharmaTech Inc. signed a collaborative research agreement with the BC Cancer Agency (BCCA) to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the company's lead oncology product, SL052, with various immunotherapeutic agents. Photodynamic therapy uses light to activate anti-cancer drugs, but has also been shown to stimulate the body's immune system to fight the disease. "Using targeted treatments with better delivery and manipulating the body's own immune system to fight the disease means patients would experience fewer side effects," says Dr. Mladen Korbelik, a senior scientist at the BCCA.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.